Countdown to 2024: #JITCTop10 - T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy bit.ly/45F6xFp @DrSapnaPatel @ANaingMD

Countdown to 2024: #JITCTop10 - Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology bit.ly/3zFQgT3 @DrJNaidoo @JulieBrahmer @EladSharonMD @cappelliMD

Countdown to 2024: #JITCTop10 - Leveraging immune resistance archetypes in solid cancer to inform next-generation anticancer therapies jitc.bmj.com/content/11/6/e… @immunegirl @BraunMDPhD @JennGuerriero @blhorton @bridgetMDPhD @TeresaKimMD @OveracreLab @MarcoRuella…

Countdown to 2024: #JITCTop10 - Vaccinating against cancer: getting to prime time bit.ly/3P0lP2t @gulleyj1 @lawfong

Countdown to 2024: #JITCTop10 - Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer bit.ly/3quY1JZ @VanMorrisMD @mdmanishshah @DrRonanKelly

keyboard_arrow_left Previous keyboard_arrow_right Next

Countdown to 2024: #JITCTop10 - mechanisms of CXCL13 enhanced antitumor immunity bit.ly/3l5ANqY @sorin_mark @mo_rezanejad @Miranda_WYu @LysDesharnais @ronirayes @DanielaQuail @PJoubertPatho @DoctorJSpicer @loganawalsh

Countdown to 2024: #JITCTop10 - Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review bit.ly/47jNdzq

Countdown to 2024: #JITCTop10 - Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden bit.ly/3L6VQ75 @VaiaFlorou @asaf_maoz @thenasheffect @Sonampuri

Countdown to 2024: #JITCTop10 - Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs bit.ly/3p7HElL @TiansterZhang @FordePatrick @EladSharonMD @RCCadvocate @DrMarc15 @md_stewart

Countdown to 2024: #JITCTop10 - Current perspectives on mass spectrometry-based immunopeptidomics: the computational angle to tumor antigen discovery bit.ly/3FAq5zU @michal_bassani

In the spirit of countdowns, we're going to count down the top ten #JITC articles from 2023 that had the highest engagements on X/Twitter. Stay tuned! #JITCTop10

In case you missed it...check out the #JITCTop10 for 2022!

Journal for ImmunoTherapy of Cancer @jitcancer

a year ago

In case you missed it...check out the #JITCTop10 for 2022!

0 0 11 2K 0

We @PaulosLab honored to be #JITCTop10 for this coolio B cell ACT CD8 T cell paper. ;)

Journal for ImmunoTherapy of Cancer @jitcancer

a year ago

We @PaulosLab honored to be #JITCTop10 for this coolio B cell ACT CD8 T cell paper. ;)

0 1 12 5K 3

Download Image

Countdown to 2023: #JITCTop10 - Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies bit.ly/3tXz49L @peters_solange @lalaniMD

Very happy to see our pre-clinical adaptive NK cell therapy paper selected among #JITCTop10 @ebba_sohlberg @AlvaroHaroun @karolinskainst @Oslounivsykehus @UniOslo_MED

Journal for ImmunoTherapy of Cancer @jitcancer

a year ago

Very happy to see our pre-clinical adaptive NK cell therapy paper selected among #JITCTop10 @ebba_sohlberg @AlvaroHaroun @karolinskainst @Oslounivsykehus @UniOslo_MED

0 6 26 5K 1

Download Image

Countdown to 2023: #JITCTop10 - Adaptive single-KIR+NKG2C+ NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia bit.ly/3DP9CaT @ebba_sohlberg @MalmbergLab

Countdown to 2023: #JITCTop10 - Antitumor strategies targeting macrophages: the importance of considering the differences in differentiation/polarization processes between human and mouse macrophages bit.ly/3VLTfmz @lea_paolini